This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.
Top Stock Reports for Apple, Comcast & Nike
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Comcast (CMCSA) and Nike (NKE).
3 MedTech Stocks in Focus on Emerging Market Prospects
by Trina Mukherjee
Emerging market countries present lucrative prospects; consequently, investors can take a look at the space.
FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR
by Zacks Equity Research
This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.
Medtronic's MiniMed 670G Shows Favorable Outcome in Europe
by Zacks Equity Research
Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
by Zacks Equity Research
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
Why Is Medtronic (MDT) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic Receives European Nod for Glucose Monitoring System
by Zacks Equity Research
Medtronic (MDT) plans to upgrade diabetes care by combining technical advancement with better user experience.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.
The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks
by Zacks Equity Research
A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.
Zacks.com featured highlights include: Lithia Motors, Medtronic, Target, Universal Forest Products and Allegiant Travel
by Zacks Equity Research
Zacks.com featured highlights include: Lithia Motors, Medtronic, Target, Universal Forest Products and Allegiant Travel
Medtronic Collaborates With Novo Nordisk for Diabetes Care
by Zacks Equity Research
This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
by Zacks Equity Research
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
Medtronic (MDT) Earns Dow Jones Sustainability Recognition
by Zacks Equity Research
Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.
BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
by Zacks Equity Research
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
Why You Should Invest in Dividend Growth Stocks
by Sweta Killa
The appeal for dividend ETFs has been rising on investors' drive for juicy yields and consistent income amid heightened uncertainty and volatility.
Medtronic (MDT) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Medtronic (MDT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MDT) Outperforming Other Medical Stocks This Year?
IoMT Becomes the Buzzword in New Age MedTech Investing
by Urmimala Biswas
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
3D Printing Gaining Popularity: 3 MedTech Stocks to Watch
by Trina Mukherjee
In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.
United Therapeutics' Trevyent NDA for PAH Accepted by FDA
by Zacks Equity Research
United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.
5 High-Flying Stocks Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Bruker (BRKR) Introduces the nanoIR3-s Broadband System
by Zacks Equity Research
The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.
ETFs to Gain as Surgical Robots Rise in Popularity
by Sweta Jaiswal, FRM
We highlight ETFs which are set to gain from an expanding surgical robotic market on factors like growing demand for automation in healthcare, rising cases of chronic diseases and ageing population.